Pain

Key Messages

  • More than half of all seriously ill patients experience pain. [1-4]
  • Many palliative care patients continue to experience unacceptably high levels of pain.
  • Under assessment is more likely among people living in residential care, patients with cognitive impairment, [5,6] patients in neonatal, paediatric and adult intensive care units, [7-9] and members of minority ethnic communities. [10]
  • The majority of pain in palliative care patients can be effectively treated using a multimodal approach and best practice management strategies. [4]
  • Pain in palliative care patients should be actively identified, carefully assessed, and treated promptly.
  • There are many pain assessment tools available to assist clinicians in identifying pain, but some of the commonly used tools are yet to be validated.
  • Choice of opioid, when managing severe pain, will depend on access to the available preparation, the patient history, the specific condition of the patient, as well as discussion with the patient on the benefits and risk of each option.
  • For non-pharmacological management there is evidence to support the use of patient education, cognitive behavioural therapy (CBT), relaxation, and music.
  • Neuropathic pain in palliative care has been identified as a considerable problem as it is difficult to assess and treat.
  • For bone pain due to metastases, external beam radiotherapy is an effective treatment.
  • Use of paracetamol in the palliative care setting is not well studied but clinically it is broadly used in older people and children.

  

  

  

PubMed Searches

Pain
Free full text only All citations About these searches
Review Collection

Evidence Summary

Definition and Prevalence

Pain is a common symptom in palliative care. It can be present as a direct result of disease processes, for example in cancer, or can be the result of effects from treatment, such as radiation or surgery. A significant amount of research into the assessment and management of pain in a palliative care context is based on patients with cancer. Pain is a frequent complication of cancer, but it is also common in many other life-limiting illnesses. [11-13]

Pain is a significant symptom in many patients accessing palliative care services and recognising its presence can be a challenge for health care professionals. The prevalence of pain in advanced, metastatic or terminal cancer has been estimated at 66 per cent. [1] This is a similar rate as seriously ill patients in home care and those with lung disease. [14,15] The rates in HIV are higher at 50 to 80 per cent. [16] Pain is also the most common symptom experienced by paediatric palliative care patients. [17] While some patients with life limiting conditions may experience pain in the early stages of their condition, [18] it is certainly true that pain is a significant clinical feature for many patients at the end of life. [19] It is one of the most common symptoms in all life-limiting illnesses with one study reporting that over 50 per cent of patients with HIV, heart disease, COPD, renal failure and cancer experiencing pain. [20] While each non-malignant life-limiting disease has its own specific pathology and specific symptoms, pain remains one of the common symptoms to most life-limiting conditions. [11]

Pain that is not well controlled causes significant distress and disability, and despite the availability of best practice approaches to pain management, [21] there is wide variability in how pain is treated in practice. [22] The effective management of pain is therefore a core element of palliative care practice.

Assessment

Identifying the type of pain the patient is experiencing is essential to guide the development of treatment plans and management options for patients. Certain conditions have a greater prevalence of neuropathic pain, for example, HIV, [23] and the assessment and management of neuropathic pain requires a unique approach. With the increasing complexity of cancer and other life-limiting illness treatments, and the longer survival of patients who have painful conditions, approaches which are holistic, multimodal, mechanism-based, and which start at diagnosis, are needed. [24,25]

In the palliative care setting, some of the important contributors to pain to consider and treat specifically are:

  • Bone metastases and their complications including pathological fractures and spinal cord compression
  • Malignant or non-healing wounds
  • Infection
  • Neuropathic pain
  • Radiotherapy / chemotherapy effects (usually short term)
  • Lymphoedema
  • Depression / anxiety / fear
  • Frailty, decreasing mobility or becoming bed-bound
  • Constipation and urinary retention.

There are a large number of guidelines available to clinicians covering pain assessment and management. Some are written specifically for palliative care services, others are relevant as they focus on specific conditions, such as neuropathic pain or cancer pain, or specific patient groups, such as paediatrics or those living in residential care. These are discussed in more detail in the section on Pain Assessment.

Treatment

Pain is a subjective, internal phenomenon and therefore can be influenced by a many internal and external factors. The biopsychosocial model of pain recognises the sensory, cognitive and social factors which contribute to the overall experience of pain. [26] A comprehensive approach to pain management begins at diagnosis, should be mechanism-based and multimodal, and must be tailored to the individual patient needs. The majority of pain in palliative care patients can be effectively treated with available medications and best practice management strategies, which includes regular assessment of pain with validated assessment tools. [17,27,28]

The World Health Organization (WHO) developed a three-step ladder model to support decision making in managing pain based on pain intensity. The model utilised a linear approach to pain with pharmacological treatments correlating from mild pain to severe pain. However, this model; does not recognise the role of non-pharmacological and interventional treatment options. [29] New approaches to treating pain are targeted at multimodal and individual treatments. [29]

Oral morphine, oxycodone and hydromorphone all have similar efficacy and toxicity in opioid naïve patients. [30] According to updated recommendations from the European Association of Palliative Care, any of these opioids can be used as first line opioids. [31] The use of simple analgesics or adjuvants may be useful to improve analgesic efficacy and reduce total opioid doses. [13] Non-pharmacological approaches to pain management can also contribute to an effective pain management plan and are often well accepted by patients.

Recent evidence-based guidelines for neuropathic pain suggest that two groups of medications may be used as first line adjuvant treatment – of the antidepressants, either tricyclics, or duloxetine or venlafaxine, and of the anticonvulsants, either gabapentin or pregabalin. [23] The evidence is weak for the use of opioids in neuropathic pain. [23]

The topics covered in the following pages will highlight the new approaches to assessing and treating pain. These topics are:

  • Barriers to Pain Management
  • Pain assessment
  • Pharmacological Management - Opioid analgesics
  • Pharmacological Management – Non-opioid analgesics
  • Non-pharmacological approaches to pain management
  • Radiotherapy and Interventional pain management.

Practice Implications

Practice implications for pain assessment and management will vary according to condition and context of care and these are dealt with in detail in the corresponding sections.

Evidence Gaps

The evidence for best practice pain management in palliative care continues to evolve. Much of the evidence about pain management comes from studies in populations potentially different from palliative care patients. [32] Studies of acute pain, single dose studies of particular analgesics, and studies in chronic non-malignant pain contribute to the evidence.

  • The prevalence of pain in non-malignant life-limiting illness needs further investigation.
  • Patients with non-malignant life limiting illnesses are more likely to not have their pain adequately assessed. [33]
  • Recommendations about managing breakthrough pain are evolving. A consensus that breakthrough opioids need to be individually titrated, rather than provided in a fixed ratio to the background opioid, has emerged in the literature. [34]
  • Subcutaneous or intravenous patient controlled analgesia devices used in the delivery of analgesics are being used more frequently outside the acute postoperative pain setting and may have a role in palliative care. [35]
  • Further research is needed to identify the most effective pain assessment tools for use in palliative care [36] and to improve processes of routine care so that pain is managed most effectively. [32] Pain is being used in a number of studies to measure quality of life in both adults [37] and children palliative care patients. [38,39]
  • Opioid rotation or switching and calculation of doses between various opioids in different populations and treatment settings is an important research area for palliative care. There is considerable variation in pharmacokinetics and pharmacodynamics of different opioids and between individual patients. The interactions of non-opioid medications may also cause alterations in pharmacokinetics. While some organisations have developed opioid dose equivalence tables there is a strong need for clinical decision making that is individually focused and opioid dosing titrated to the patient’s unique situation. [31,40-43]
  • Research in the treatment of neuropathic pain is needed to strengthen the evidence base in palliative care. [23]
  • The role of non-opioid analgesics and interventional pain management approaches remains poorly researched in the palliative care setting.
  • The role of ‘Medicinal Cannabis’ remains controversial in palliative pain management. While public interest in its use has increased there remains low quality evidence for its addition to the pain management plan. [44-46]
  • Palliative care services may now be caring for patients with a history of drug abuse and addiction or the risk of addiction and diversion. Guidelines are being developed to help clinicians and more research is needed to validate screening tools. [47]
  • Evidence-based protocols and educational processes within institutions should be developed to improve the quality of care.

 

  1. van den Beuken-van Everdingen MH, Hochstenbach LM, Joosten EA, Tjan-Heijnen VC, Janssen DJ. Update on Prevalence of Pain in Patients With Cancer: Systematic Review and Meta-Analysis. J Pain Symptom Manage. 2016 Jun;51(6):1070-1090.e9. Epub 2016 Apr 23.
  2. Chen YW, Camp PG, Coxson HO, Road JD, Guenette JA, Hunt MA, et al. A Comparison of Pain, Fatigue, Dyspnea and their Impact on Quality of Life in Pulmonary Rehabilitation Participants with Chronic Obstructive Pulmonary Disease. COPD. 2018 Feb;15(1):65-72. doi: 10.1080/15412555.2017.1401990. Epub 2017 Dec 11.
  3. Fleishman TT, Dreiher J, Shvartzman P. Pain in Maintenance Hemodialysis Patients: A Multicenter Study. J Pain Symptom Manage. 2018 Aug;56(2):178-184. doi: 10.1016/j.jpainsymman.2018.05.008. Epub 2018 Jun 20.
  4. Coyne P, Mulvenon C, Paice JA. American Society for Pain Management Nursing and Hospice and Palliative Nurses Association Position Statement: Pain Management at the End of Life. Pain Manag Nurs. 2018 Feb;19(1):3-7. doi: 10.1016/j.pmn.2017.10.019. Epub 2017 Dec 16.
  5. Greenwood N, Menzies-Gow E, Nilsson D, Aubrey D, Emery CL, Richardson A. Experiences of older people dying in nursing homes: a narrative systematic review of qualitative studies. BMJ Open. 2018 Jun 4;8(6):e021285. doi: 10.1136/bmjopen-2017-021285.
  6. Ellis-Smith C, Evans CJ, Bone AE, Henson LA, Dzingina M, Kane PM, et al. Measures to assess commonly experienced symptoms for people with dementia in long-term care settings: a systematic review. BMC Med. 2016 Feb 26;14:38. doi: 10.1186/s12916-016-0582-x.
  7. Nguyen LT, Cooperberg DB, Spear ML. Introduction of triggers for palliative care consultation improves utilization and satisfaction within a level four NICU. J Perinatol. 2018 May;38(5):574-579. doi: 10.1038/s41372-018-0067-1. Epub 2018 May 8.
  8. Beckstrand RL, Lamoreaux N, Luthy KE, Macintosh JL. Critical Care Nurses' Perceptions of End-of-Life Care Obstacles: Comparative 17-Year Data. Dimens Crit Care Nurs. 2017 Mar/Apr;36(2):94-105. doi: 10.1097/DCC.0000000000000234.
  9. Threapleton DE, Chung RY, Wong SYS, Wong ELY, Kiang N, Chau PYK, et al. Care Toward the End of Life in Older Populations and Its Implementation Facilitators and Barriers: A Scoping Review. J Am Med Dir Assoc. 2017 Dec 1;18(12):1000-1009.e4. doi: 10.1016/j.jamda.2017.04.010. Epub 2017 Jun 13.
  10. Gardner DS, Doherty M, Bates G, Koplow A, Johnson S. Racial and Ethnic Disparities in Palliative Care: A Systematic Scoping Review. Families in Society. 2018 Dec;99(4):301-316. doi.org/10.1177/1044389418809083
  11. Moens K, Higginson IJ, Harding R; EURO IMPACT. Are there differences in the prevalence of palliative care-related problems in people living with advanced cancer and eight non-cancer conditions? A systematic review. J Pain Symptom Manage. 2014 Oct;48(4):660-77. doi: 10.1016/j.jpainsymman.2013.11.009. Epub 2014 May 5.
  12. Fine PG, Davis M, Muir C, Schwind D, Haileab B. Bridging the gap: pain medicine and palliative care. Pain Med. 2013 Sep;14(9):1277-9. doi: 10.1111/pme.12187. Epub 2013 Jun 27.
  13. Schüchen RH, Mücke M, Marinova M, Kravchenko D, Häuser W, Radbruch L, et al. Systematic review and meta-analysis on non-opioid analgesics in palliative medicine. J Cachexia Sarcopenia Muscle. 2018 Dec;9(7):1235-1254. doi: 10.1002/jcsm.12352. Epub 2018 Oct 29.
  14. Davidson JGS, Guthrie DM. The Influence of Physical and Psychosocial Factors on Disruptive Pain Among Seriously Ill Home Care Patients. J Palliat Care. 2017;32(2):61-68.
  15. Peng JK, Hepgul N, Higginson IJ, Gao W. Symptom prevalence and quality of life of patients with end-stage liver disease: A systematic review and meta-analysis. Palliat Med. 2019 Jan;33(1):24-36. doi: 10.1177/0269216318807051. Epub 2018 Oct 22.
  16. Sabin CA, Harding R, Bagkeris E, Nkhoma K, Post FA, Sachikonye M, et al. Pain in people living with HIV and its association with health care resource use, well being and functional status. AIDS. 2018 Nov 28;32(18):2697-2706. doi: 10.1097/QAD.0000000000002021.
  17. Thomas R, Phillips M, Hamilton RJ. Pain Management in the Pediatric Palliative Care Population. J Nurs Scholarsh. 2018 May 5. doi: 10.1111/jnu.12389. [Epub ahead of print]
  18. Rana AQ, Qureshi AR, Siddiqui O, Sarfraz Z, Rana R, Shtilbans A. Prevalence of pain in atypical parkinsonism: a systematic review and meta-analysis. J Neurol. 2018 Sep 20. doi: 10.1007/s00415-018-9049-7. [Epub ahead of print]
  19. Kehl KA, Kowalkowski JA. A systematic review of the prevalence of signs of impending death and symptoms in the last 2 weeks of life. Am J Hosp Palliat Care. 2013 Sep;30(6):601-16. doi: 10.1177/1049909112468222. Epub 2012 Dec 12.
  20. Solano JP, Gomes B, Higginson IJ. A comparison of symptom prevalence in far advanced cancer, AIDS, heart disease, chronic obstructive pulmonary disease and renal disease. J Pain Symptom Manage. 2006 Jan;31(1):58-69.
  21. Dy SM. Evidence-based approaches to pain in advanced cancer. Cancer J. 2010 Sep-Oct;16(5):500-6.
  22. Zerzan J, Benton K, Linnebur S, O'Bryant C, Kutner J. Variation in pain medication use in end-of-life care. J Palliat Med. 2010 May;13(5):501-4. doi: 10.1089/jpm.2009.0406.
  23. Finnerup NB, Attal N, Haroutounian S, McNicol E, Baron R, Dworkin RH, et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol. 2015 Feb;14(2):162-73. doi: 10.1016/S1474-4422(14)70251-0. Epub 2015 Jan 7.
  24. Raphael J, Ahmedzai S, Hester J, Urch C, Barrie J, Williams J, et al. Cancer pain: part 1: Pathophysiology; oncological, pharmacological, and psychological treatments: a perspective from the British Pain Society endorsed by the UK Association of Palliative Medicine and the Royal College of General Practitioners. Pain Med. 2010 May;11(5):742-64. doi: 10.1111/j.1526-4637.2010.00840.x.
  25. Raphael J, Hester J, Ahmedzai S, Barrie J, Farqhuar-Smith P, Williams J, et al. Cancer pain: part 2: physical, interventional and complimentary therapies; management in the community; acute, treatment-related and complex cancer pain: a perspective from the British Pain Society endorsed by the UK Association of Palliative Medicine and the Royal College of General Practitioners. Pain Med. 2010 Jun;11(6):872-96. doi: 10.1111/j.1526-4637.2010.00841.x. Epub 2010 Apr 26.
  26. Puntillo K, Naidu RK. Measurement of Chronic Pain and Opioid Use Evaluation in Community-Based Persons with Serious Illnesses. J Palliat Med. 2018 Mar;21(S2):S43-S51. doi: 10.1089/jpm.2017.0457. Epub 2017 Nov 1.
  27. Bullock L, Bedson J, Jordan JL, Bartlam B, Chew-Graham CA, Campbell P. Pain assessment and pain treatment for community-dwelling people with dementia: A systematic review and narrative synthesis. Int J Geriatr Psychiatry. 2019 Jun;34(6):807-821. doi: 10.1002/gps.5078. Epub 2019 Apr 8.
  28. Schofield P. The Assessment of Pain in Older People: UK National Guidelines. Age Ageing. 2018 Mar 1;47(suppl_1):i1-i22. doi: 10.1093/ageing/afx192.
  29. Cuomo A, Bimonte S, Forte CA, Botti G, Cascella M. Multimodal approaches and tailored therapies for pain management: the trolley analgesic model. J Pain Res. 2019;12:711–714. Published 2019 Feb 19. doi:10.2147/JPR.S178910
  30. Caraceni A, Pigni A, Brunelli C. Is oral morphine still the first choice opioid for moderate to severe cancer pain? A systematic review within the European Palliative Care Research Collaborative guidelines project. Palliat Med. 2011 Jul;25(5):402-9.
  31. Caraceni A, Hanks G, Kaasa S, Bennett MI, Brunelli C, Cherny N, et al. Use of opioid analgesics in the treatment of cancer pain:evidence-based recommendations from the EAPC. Lancet Oncol. 2012 Feb;13(2):e58-68.
  32. Carr DB, Goudas LC, Balk EM, Bloch R, Ioannidis JP, Lau J. Evidence report on the treatment of pain in cancer patients. J Natl Cancer Inst Monogr. 2004;(32):23-31.
  33. See D, Le B, Gorelik A, Eastman P. Symptom burden in malignant and non-malignant disease on admission to a palliative care unit. BMJ Support Palliat Care. 2019 Feb 4. pii: bmjspcare-2018-001560. doi: 10.1136/bmjspcare-2018-001560. [Epub ahead of print]
  34. Davies AN, Elsner F, Filbet MJ, Porta-Sales J, Ripamonti C, Santini D, et al. Breakthrough cancer pain (BTcP) management: a review of international and national guidelines. BMJ Support Palliat Care. 2018 Sep;8(3):241-249. doi: 10.1136/bmjspcare-2017-001467. Epub 2018 Jun 6.
  35. Nijland L, Schmidt P, Frosch M, Wager J, Hübner-Möhler B, Drake R, et al. Subcutaneous or intravenous opioid administration by patient-controlled analgesia in cancer pain: a systematic literature review. Support Care Cancer. 2019 Jan;27(1):33-42. doi: 10.1007/s00520-018-4368-x. Epub 2018 Jul 28.
  36. Holen J, Hjermstad M, Loge J, Fayers P, Caraceni A, De Conno F, Forbes K, Fürst CJ, Radbruch L, Kaasa S. Pain assessment tools: is the content appropriate for use in palliative care? J Pain Symptom Manage. 2006 Dec;32(6):567-80.
  37. Higginson IJ, Simon ST, Benalia H, Downing J, Daveson BA, Harding R, et al. Republished: which questions of two commonly used multidimensional palliative care patient reported outcome measures are most useful? Results from the European and African PRISMA survey. Postgrad Med J. 2012 Aug;88(1042):451-7.
  38. Downing J, Namisango E, Harding R. Outcome measurement in paediatric palliative care: lessons from the past and future developments. Ann Palliat Med. 2018 Oct;7(Suppl 3):S151-S163. doi: 10.21037/apm.2018.04.02. Epub 2018 Jun 19
  39. Friedel M, Aujoulat I, Dubois AC, Degryse JM. Instruments to Measure Outcomes in Pediatric Palliative Care: A Systematic Review. Pediatrics. 2019 Jan;143(1). pii: e20182379. doi: 10.1542/peds.2018-2379. Epub 2018 Dec 7.
  40. Lasheen W, Walsh D, Mahmoud F, Sarhill N, Rivera N, Davis M, et al. The intravenous to oral relative milligram potency ratio of morphine during chronic dosing in cancer pain.  2010 Jan;24(1):9-16. doi: 10.1177/0269216309346595. Epub 2009 Nov 12.
  41. Shaheen PE, Walsh D, Lasheen W, Davis MP, Lagman RL. Opioid equianalgesic tables: are they all equally dangerous? J Pain Symptom Manage. 2009 Sep;38(3):409-17. doi: 10.1016/j.jpainsymman.2009.06.004.
  42. Dale O, Moksnes K, Kaasa S, European Palliative Care Research Collaborative pain guidelines: opioid switching to improve analgesia or reduce side effects. A systematic review. Palliat Med. 2011 Jul;25(5):494-503. doi: 10.1177/0269216310384902.
  43. Schuster M, Bayer O, Heid F, Laufenberg-Feldmann R. Opioid Rotation in Cancer Pain Treatment. Dtsch Arztebl Int. 2018 Mar 2;115(9):135-142. doi: 10.3238/arztebl.2018.0135.
  44. Darkovska-Serafimovska M, Serafimovska T, Arsova-Sarafinovska Z, Stefanoski S, Keskovski Z, Balkanov T. Pharmacotherapeutic considerations for use of cannabinoids to relieve pain in patients with malignant diseases. J Pain Res. 2018 Apr 23;11:837-842. doi: 10.2147/JPR.S160556. eCollection 2018.
  45. Hauser W, Serafimovska T, Arsova-Sarafinovska Z, Stefanoski S, Keskovski Z, Balkanov T. Cannabinoids in Pain Management and Palliative Medicine. Dtsch Arztebl Int, 2017. 114(38): p. 627-634.
  46. Mücke M, Weier M, Carter C, Copeland J, Degenhardt L, Cuhls H, et al. Systematic review and meta-analysis of cannabinoids in palliative medicine. J Cachexia Sarcopenia Muscle. 2018 Apr;9(2):220-234. doi: 10.1002/jcsm.12273. Epub 2018 Feb 5.
  47. Kata V, Novitch MB, Jones MR, Anyama BO, Helander EM, Kaye AD. Opioid addiction, diversion, and abuse in chronic and cancer pain. Curr Opin Support Palliat Care. 2018 Jun;12(2):124-130. doi: 10.1097/SPC.0000000000000333.

Last updated 05 November 2019